| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Dannielle Appelhans is Director at GBIO and has filed Form 4s across 2 companies. Dannielle Appelhans's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $163K at current prices.
The biggest single holding is HALO (~$149K) as Director.
Dannielle Appelhans has 7 Form 4 filings on record from July 2022 to September 2026, across 2 companies: Director at Halozyme Therapeutics (HALO), 2026; Director at Generation Bio (GBIO), 2022–2025.
The 9 reported transactions were 5 option or other derivative awards, 3 open-market purchases and 1 stock award.
Counted by filing, the open-market trades come to 2 purchases worth about $32K and no sales.
The largest open-market purchase was 12,000 shares of GBIO at an average $1.50 on December 4, 2023, about $18K. Twelve months later GBIO was down 9%.